Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Milad Mirmoghtadaei"'
Autor:
Maryam Nourizadeh, Elham Feizabadi, Milad Mirmoghtadaei, Ashraf Mohammadi, Mohammad Reza Fazlollahi, Leila Moradi, Zahra Pourpak
Publikováno v:
Iranian Journal of Immunology, Vol 20, Iss 4, Pp 400-409 (2023)
Background: Few studies have evaluated COVID-19 vaccine efficacy in patients with inborn errors of immunity (IEI).Objective: To evaluate the levels of antibody (Ab) production and function after COVID-19 vaccination in IEI patients with phagocytic, c
Externí odkaz:
https://doaj.org/article/eee3004f26894a629f53369569f3a4c7
Autor:
Saieh Hajighasemlou, Mohsen Nikbakht, Saeedreza Pakzad, Abdolnaser Azadbakht, Samad Muhammadnejad, Milad Mirmoghtadaei, Safoora Gharibzadeh, Iman Seyhoun, Javad Verdi
Publikováno v:
Veterinary Medicine and Science, Vol 8, Iss 5, Pp 2086-2091 (2022)
Abstract Background Hepatocellular carcinoma (HCC) is the fifth most diagnosed cancer and the second leading cause of cancer‐related deaths worldwide. Sorafenib is the standard treatment used in the advanced stages of HCC. Cell therapy with mesench
Externí odkaz:
https://doaj.org/article/1b62b91eeaa9473bb21a5f9ee1a899e2
Autor:
Milad Mirmoghtadaei, Alireza Soltani Khaboushan, Bahareh Mohammadi, Matin Sadr, Hooman Farmand, Zahra Hassannejad, Abdol-Mohammad Kajbafzadeh
Publikováno v:
Regenerative medicine. 17(12)
Organ transplantation is limited by donor organ shortage throughout the world. Tissue engineering involves the use of biocompatible scaffold upon which cells can grow into functional tissues. Researchers have already experimented with kidney tissue e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da07d0a14ca15ca24860e95e6fdfbc13
https://pubmed.ncbi.nlm.nih.gov/36154467
https://pubmed.ncbi.nlm.nih.gov/36154467
Autor:
null Saieh Hajighasemlou, null Mohsen Nikbakht, null Saeedreza Pakzad, null Abdolnaser Azadbakht, null Samad Muhammadnejad, null Milad Mirmoghtadaei, null Safoora Gharibzadeh, null Iman Seyhoun, null Javad Verdi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce5d7c20fec9e125cf0475e1154a8839
https://doi.org/10.1002/vms3.886/v4/response1
https://doi.org/10.1002/vms3.886/v4/response1
Autor:
Faezeh Hosseinzadeh, Iman Seyhoun, Jafar Ai, Benyamin Parseh, Zeinab Ghazvinian, Javad Verdi, Shahrokh Abdolahi, Milad Mirmoghtadaei, Mahdi Shadnoush, Seyed Moein Seyhoun, Saieh Hajighasemlou
Publikováno v:
Asian Pacific Journal of Cancer Prevention : APJCP
Objective: Hepatocellular carcinoma (HCC) is the most common liver malignancy. Sorafenib is the first-line systemic treatment for advanced HCCs. However, due to safety concerns, researchers are now looking for ways to boost the efficacy of the medica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::845320b8fe07d81b930de687182f86af
https://doi.org/10.31557/apjcp.2019.20.1.263
https://doi.org/10.31557/apjcp.2019.20.1.263
Autor:
Jafar Ai, Iman Seyhoun, Safoora Gharibzadeh, Saieh Hajighasemlou, Fariba Zafari, Javad Verdi, S R Pakzad, Mohsen Nikbakht, Milad Mirmoghtadaei, Samad Muhammadnejad
Publikováno v:
Evidence-Based Complementary and Alternative Medicine, Vol 2020 (2020)
Evidence-based Complementary and Alternative Medicine : eCAM
Evidence-based Complementary and Alternative Medicine : eCAM
Hepatocellular carcinoma (HCC) is the fifth most commonly diagnosed cancer and the second most common cause of cancer-related death worldwide. Sorafenib (Sora) is used as a targeted therapy for HCC treatment. Mesenchymal stem cells (MSCs) are applied
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c18506d6e2984f8e1b33c690a391155
Autor:
Milad Mirmoghtadaei, Faezeh Hosseinzadeh, Jafar Ai, Saieh Hajighasemlou, Ali Akbar Alizadeh, Iman Seyhoun, Mohsen Nikbakht, Javad Verdi, Seyed Moein Seyhoun, Samad Muhammadnejad
Publikováno v:
Journal of Cellular Physiology. 234:9495-9503
Aim Hepatocellular carcinoma (HCC) is the most common liver malignancy and the second leading cause of cancer-related deaths in the world. Sorafenib is the first-line treatment of HCC. Although sorafenib has positive effects on the survival of patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::addb1cdc24cb991b7489649ca91c563f
https://doi.org/10.1002/jcp.27637
https://doi.org/10.1002/jcp.27637
Autor:
Saieh, Hajighasemlou, Saeedreza, Pakzad, Jafar, Ai, Samad, Muhammadnejad, Milad, Mirmoghtadaei, Faezeh, Hosseinzadeh, Safoora, Gharibzadeh, Amir, Kamali, Akbar, Ahmadi, Javad, Verdi
Publikováno v:
Asian Pacific Journal of Cancer Prevention : APJCP
Background: Hepatocellular carcinoma (HCC) is the fifth most diagnosed cancer and the third leading cause of cancer-related death. sorafenib is used as a standard therapy to treat HCC. mesenchymal stromal cells (MSCs) have also been used to suppress
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f9687fac0ae534c8566a2d12d32ceda7
https://pubmed.ncbi.nlm.nih.gov/29936790
https://pubmed.ncbi.nlm.nih.gov/29936790
Publikováno v:
Hemoglobin. 39:75-80
β-Thalassemia (β-thal) is a type of hereditary anemia affecting hemoglobin (Hb) synthesis causing severe chronic anemia in homozygous patients. Regular blood transfusions are the mainstay treatment for this type of anemia. In turn, this leads to ir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7861a0bad6ce56d1356ee31189a3fc0a
https://doi.org/10.3109/03630269.2014.1003224
https://doi.org/10.3109/03630269.2014.1003224
Autor:
Milad Mirmoghtadaei, Marjan Gharagozloo, Mahdi Ghatreh Samani, Nafiseh Esmaeil, Behjat Moayedi
Publikováno v:
Journal of Advances in Medical and Pharmaceutical Sciences. 2:52-56
Background: Despite appropriate chelation therapy with desferrioxamine, iron deposition in visceral organs causes tissue damage in thalassemia major patients. Excess iron can generate reactive oxygen species (ROS) that may lead to cell death and apop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2ed7610ebce24db36aa23266f079fac4
https://doi.org/10.9734/jamps/2015/12818
https://doi.org/10.9734/jamps/2015/12818